Diffuse cutaneous systemic sclerosis
Gene expression changes reflect clinical response in a placebo controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis
... dcSSc: Diffuse cutaneous systemic sclerosis; DLCO: Diffusing capacity of the lung for carbon monoxide; ESR: Erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; EUSTAR: ...
14
Estimating Benefits from Immunesuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from the Canadian Scleroderma Research Group
... Objective: To determine the efficacy of immunesuppressive treatment over 1 year in early diffuse cutaneous systemic sclerosis (dcSSc). Methods: dcSSc patients with less than 3 years disease ...
7
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)
... fees from 4D Science, Actelion, Active Biotech, Bayer, Biogenidec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, P fi zer, ...
14
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).
... fees from 4D Science, Actelion, Active Biotech, Bayer, Biogenidec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, P fi zer, ...
12
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial
... Methods Study Design and Participants The ASTIS trial was an investigator-initiated, randomized, openlabel, parallel-group trial conducted in 10 countries at 29 centers with access to a [r] ...
9
Vol 28, No 3 (2018)
... skin sclerosis – diffuse cutaneous systemic sclerosis (dcSSc) and limited cutaneous systemic sclerosis ...Limited cutaneous systemic sclerosis ...
5
The cumulative number of micro haemorrhages and micro thromboses in nailfold videocapillaroscopy is a good indicator of disease activity in systemic sclerosis: a validation study of the NEMO score
... limited cutaneous systemic sclerosis (lcSSc) or diffuse cutaneous systemic sclerosis (dcSSc) following the LeRoy et ...
9
Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor β pathway in patients with systemic sclerosis
... dcSSc: diffuse cutaneous systemic sclerosis; EDTA: ethylenediaminetetraacetic acid; EGTA: ethyleneglycoltetraacetic acid; HC: healthy controls; hnRNP L: heterogeneous nuclear ribonucleoprotein ...
13
KCNA5 gene is not confirmed as a systemic sclerosis related pulmonary arterial hypertension genetic susceptibility factor
... dcSSc: diffuse cutaneous systemic sclerosis; hRCT: High-resolution computed tomography; HWE: Hardy-Weinberg equilibrium; K: potassium; KCNA5: potassium voltage- gated channel shaker-related ...
6
Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
... limited cutaneous systemic scle- rosis (lSSc), with skin sclerosis limited to extremities and face [20], and 13 had diffuse cutaneous systemic sclerosis (dSSc), with skin ...
6
Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS I and SLS II)
... Methods: MCID estimates for the mRSS at 12 months were calculated using three anchors: change in scores on the Health Assessment Questionnaire- Disability Index from baseline to 12 months, change in scores on the Patient ...
9
Therapeutic targets in systemic sclerosis
... of systemic sclerosis (SSc) remains elusive, but significant advances over the past few years have improved our understanding of the underlying pathogenic processes and identified key pathways and mediators ...
5
Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis
... Institutional review boards at Boston University, University of Pittsburgh, and Tufts University ap- proved the collection of all serum samples and clinical data. Written informed consent was obtained from all patients ...
10
Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis
... This was a placebo-controlled study of 20 patients with established diffuse cutaneous SSc, defined by disease duration of at least 36 months from first non-Raynaud’s symptom. Subjects were randomly ...
10
Plexin D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis
... Systemic sclerosis (SSc) is a multisystem autoimmune dis- ease of unknown etiology characterized by vascular dam- age, activation of the immune system, and excessive deposition of collagen in the skin and ...
12
The effects of upper and lower limb exercise on the microvascular reactivity in limited cutaneous systemic sclerosis patients
... Systemic sclerosis (SSc) is an idiopathic systemic auto- immune disease characterized by an ongoing cutaneous and visceral fibrosis, fibroproliferative vasculopathy and immunologic ...
11
Exocrine pancreatic function is preserved in systemic sclerosis
... SSc was defined according to the 2013 American Con- gress of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria, and patients were subdivided into diffuse cutaneous SSc (dcSSc) and lim- ...
8
Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study
... areas are examined by clinical palpation and scored on the basis of judgement of skin thickness on a 4-point ordinal scale. Because the extent of skin disease corre- lates with the disease course, patients are grouped ...
7
BSR and BHPR guideline for the treatment of systemic sclerosis
... stage diffuse cutaneous SSc and becomes less intrusive once the disease ...plateaus. Cutaneous telangiectasia may be widespread especially over the hands and face and may present as a major cosmetic ...
24
Systemic sclerosis sine scleroderma
... Systemic sclerosis is a rare generalized disease with scleroderma, ...subsets, diffuse and limited forms. The subset known as systemic sclerosis sine scleroderma (ssSSc) is a very rare ...
6